An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Trial details
- Registry ID
- NCT07020819
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as ANX005
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)NCT07020819 | ANNX | Phase 3 | Recruiting | 2027-05-31Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |